An Efficacy and Safety Study of Sodium Oligomannate (GV-971) for the Treatment of Alzheimer's Disease
Status:
Not yet recruiting
Trial end date:
2029-12-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to confirm the clinical efficacy and mechanism of action
of GV-971, and identify incidence of known adverse reactions in long-term use and observe new
adverse reactions, providing more guidance for clinical use.